The National Key Research and Development Program for Innovative Drugs for Alzheimer's Disease has been launched in Shanghai.

On March 12, the kickoff meeting of the national key research and development program for innovative drugs, "Research on Novel Mechanisms Targeting Alzheimer's Disease Chemical Innovation Drugs," was held in Shanghai. Wanbang Pharmaceutical Group, as a core participating unit, jointly launched this national-level innovative drug development project for Alzheimer's disease, marking a significant step for the company in the research and development of drugs for major diseases in the central nervous system field.